Reported 23 days ago
Analyst Yi Chen of H.C. Wainwright has reaffirmed a Buy rating for Opko Health Inc. (NASDAQ: OPK) and maintained a price target of $3.00, despite a drop in Q1 2025 revenue to $149.9 million. The outlook remains positive as the company anticipates total revenue for 2025 to be between $675-685 million, bolstered by potential profitability from an upcoming transaction with Labcorp and advancements in its obesity treatment solutions.
Source: YAHOO